A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Ontology highlight
ABSTRACT: This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity.
The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator’s existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
DISEASE(S): Solid Tumour,Selected Solid Tumours; - Cutaneous Melanoma - Pancreatic Ductal Adenocarcinoma- Ovarian Cancer- Colorectal Adenocarcinoma- Hepatocellular Carcinoma- Gallbladder Cancer And Cholangiocarcinoma- Uveal Melanoma- Gastric Adenocarcinoma (including Ge Junction)- Estrogen Receptor Positive Breast Cancer- Anaplastic Thyroid Cancer,Selected Solid Tumours; - Cutaneous Melanoma - Pancreatic Ductal Adenocarcinoma- Ovarian Cancer- Colorectal Adenocarcinoma- Hepatocellular Carcinoma- Gallbladder Cancer And Cholangiocarcinoma...,Cancer
PROVIDER: 2288968 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA